Navigation Links
Talaris Advisors Attracts Veteran Team of Strategic Drug Development Managers

Biotech leaders enable Talaris’ capacity to deliver unprecedented, cross-functional expertise for all phases of drug development.

(PRWEB) February 22, 2010 -- In a move that forms one of biotech's most experienced strategic drug development groups, a team of veteran industry executives has joined Talaris Advisors, strengthening the company's capacity to provide expertise for all phases of drug development. Talaris works with biotech managers, companies and investors to optimize their use of capital and maximize exit outcomes for drug development programs.

Led by Mark J. Pykett, Chief Executive Officer, the Talaris management team has added the following industry veterans: Noel Cusack, PhD, Senior Vice President Nonclinical Development; Susan Flint, Senior Vice President Drug Development; Mark R. Hurtt, MD, Chief Medical Officer; Richard Thorn, PhD, Senior Vice President CMC; and James Weston, Senior Vice President Regulatory Affairs and Quality.

"Real strategic drug development expertise is determined by a team's insight and ability to accelerate milestones when taking a project through a wide range of regulatory scenarios and by creating a range of exit options based on the commercial and medical value of the assets. Our clients and investors are excited by Talaris’ expansion because it confirms our ability to provide this level of expertise and deftly address the complexities of drug development particularly in the current environment,” comments Mark J. Pykett, Talaris CEO. "Each new manager is a distinguished leader who has an average of 30 years of experience, in addition to having important networks and relationships to provide the best performance outcomes for drug compounds and investors."

By any measure, the drug development industry is challenged by the escalating cost and time it takes to develop drugs combined with increasingly complex and challenging regulatory, reimbursement and financing environments. Biotech leaders are working hard to find ways to improve both efficiency and effectiveness in drug development without losing key drivers for innovation. Biotech companies and investors engage Talaris to avoid the typical ramp-up, wind-down or carrying costs associated with drug development management while delivering integrated risk and cost optimized development programs.

The Talaris management team is composed of recognized leaders whose expertise spans the continuum of all key development disciplines: non-clinical, regulatory, medical, clinical operations, manufacturing and quality.

The industry veterans enhance Talaris’ capacity to manage projects strategically and successfully, having managed hundreds of development programs, clinical trials and regulatory submissions. In their careers with companies such as Pfizer, DuPont, Baxter and others, the team has taken over 30 products through to the market.

About Talaris Advisors
Talaris Advisors works with biotech managers, companies and investors to optimize the use of capital and exit outcomes for drug development programs. Veteran team members, averaging 30 years of drug development experience, design and implement strategies that improve success rates, build multiple exit options and maximize investment returns for therapeutic drug assets. We align the commercial and regulatory requirements of drug candidates in development programs to reduce risk and time factors in pre-IND to Phase II proof-of-concept development, improving their odds for regulatory and commercial success. For investors, our integrated portfolio approach diversifies intrinsic investment risks. Members of the Talaris team have successfully completed more than 125 clinical studies and advanced more than 30 drug products through to the market. The company is headquartered in Hopkinton, Massachusetts. Please visit Talaris at


Read the full story at

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Lincoln Financial Advisors to Provide Exclusive Services to American Osteopathic Association Members
2. FDA Advisors Declare FDA Science and Mission at Risk
3. Perceptive Informatics Appoints Medical Imaging Scientific Advisors
4. NBA Legend Dikembe Mutombo Joins Opportunity International Board of Advisors; Opens Doors in Democratic Republic of Congo
5. FDA Advisors Declare FDA Science and Mission at Risk
6. Brian Bastis Elected as National CPA Health Care Advisors Association Executive Committee President
7. Cosmetic Bootcamp Announces Record Attendance and Sponsorship and Names Members of Its Board of Advisors
8. Cline Davis & Mann Launches Platform Advisors(TM), a New Division to Provide Integrated Strategic and Scientific Consulting Services for the Pharmaceutical, Biotechnology, and Medical Device Industry
9. As Consumers Feel Financial Burden of Increasing Health Care Costs, Health Plans Have Opportunity to Address Unmet Consumer Needs and Become Trusted Advisors
10. SINOL USA, Inc. and Strategic Pharmaceutical Advisors, Inc. to Enter a Marketing Agreement for SINOL Nasal Spray
11. Emageon Selects Jefferies & Company and SunTrust Robinson Humphrey as Advisors
Post Your Comments:
Related Image:
Talaris Advisors Attracts Veteran Team of Strategic Drug Development Managers 
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... Those ... deal with these feelings, many turn to unhealthy avenues, such as drug or alcohol ... of Marne, Michigan, has released tools for healthy coping following a traumatic event. , ...
(Date:6/24/2016)... ... , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys ... peers for this recognition are considered among the top 2 percent of lawyers practicing ... members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. ...
(Date:6/24/2016)... ... 24, 2016 , ... People across the U.S. are sharpening their pencils and ... essay contest in which patients and their families pay tribute to a genetic counselor ... National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... Improvements Act of 1976, as amended ("HSR"), with respect ... Nasdaq: CPXX ) expired effective June 24, ... As previously announced on May 31, 2016, Jazz Pharmaceuticals ... which Jazz Pharmaceuticals has commenced a tender offer for ...
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, Inc., ... development and manufacturing of collagen and mineral based ... today that Bill Messer has joined ... to further leverage the growing portfolio of oral ... Bill joins the Collagen Matrix executive ...
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... addition of the "Structural Electronics 2015-2025: Applications, ... In-Mold Electronics, Smart ... Integrated Photovoltaics Structural electronics involves ... as load-bearing, protective structures, replacing dumb structures such ...
Breaking Medicine Technology: